Tyler Shultz warns AI firms could mislead investors amid boom
Theranos whistleblower Tyler Shultz says the AI boom could make it easier for companies to mislead investors, reviving lessons from the blood-testing firm’s fraud. He argues that investment decisions should involve stronger scrutiny because funding gives founders considerable power.
Shultz says it is difficult to assess whether an AI product is genuinely innovative or merely a wrapper around tools such as ChatGPT. Theranos reached a peak valuation of about $10 billion despite its technology not working as claimed; its tests were often run on third-party equipment, and its investors included wealthy individuals and families.
In short
- Shultz warns AI makes investor due diligence difficult.
- He says that creates an opening for deception.
- Theranos reached a peak valuation of about $10 billion.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
The rapid growth of AI and the difficulty of judging what a product actually does can leave investors vulnerable to exaggerated claims. Shultz’s experience with Theranos supports the case for careful technical and financial scrutiny, since investors’ money can give founders substantial influence and misleading claims can cause serious harm.
The case against
AI is a fast-moving field in which products and capabilities can be difficult to assess even in good faith, so uncertainty alone does not show that firms are misleading investors. Heavy scrutiny may also make it harder for newer companies to attract funding and develop useful technology; investors can instead weigh evidence, risks and potential returns as part of their own due diligence.
Explained simply
Theranos was a US blood-testing company founded by Elizabeth Holmes. It claimed its technology could run many tests using just a small amount of blood, but the system did not work as promised; the company’s value was once estimated at about $10 billion.
Tyler Shultz worked at Theranos and later became a whistleblower, raising concerns about the company’s testing claims. His experience is relevant to AI firms because investors may find it hard to judge whether a product is genuinely new or mainly built around existing tools such as ChatGPT.
Investors provide companies with money to grow, and their decisions can give founders significant influence. The Theranos case is one example of why scrutiny of a company’s claims matters when large sums are being invested.
Read the full article at the source →
Originally published by TechCrunch as “Theranos whistleblower Tyler Shultz warns that the AI boom is ‘a great opportunity to go deceive people’”.